EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE

Alzheimer's disease is the most common degenerative disease of brain. Nowadays, the most common treatment being used to slow down disease progression, include Donepezil , Rivastigmine and Galantamine, which all of them act as inhibitors of acetyl cholinesterase. General purpose of our study was...

Full description

Bibliographic Details
Main Authors: R. Abolfazli, S. Ghazanshahi M. Nazeman
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2008-04-01
Series:Acta Medica Iranica
Subjects:
Online Access:https://acta.tums.ac.ir/index.php/acta/article/view/3451
_version_ 1811265854390665216
author R. Abolfazli
S. Ghazanshahi M. Nazeman
author_facet R. Abolfazli
S. Ghazanshahi M. Nazeman
author_sort R. Abolfazli
collection DOAJ
description Alzheimer's disease is the most common degenerative disease of brain. Nowadays, the most common treatment being used to slow down disease progression, include Donepezil , Rivastigmine and Galantamine, which all of them act as inhibitors of acetyl cholinesterase. General purpose of our study was to show effects of treatment with Donepezil and Rivastigmine, as two drugs that commonly used for treatment of AD in Iran and to compare these effects between two drugs. Samples selected from patients who had Alzheimer` disease with DSM IV criteria and were candidate of receiving Donepezil or Rivastigmine, as treatment of AD, for the first time. We used four neuropsychological tests including MMSE, NPI, Clock and Bender to assess patient's cognitive and behavioral changes during treatment with two drugs. Patients divided to two groups (each group 35 cases); Patients with plan of taking Donepezil entered into one of the groups and patients with plan of taking Rivastigmine entered into another. The four tests were completed once before starting treatment and then, 1 month, 3 months and 6 months after treatment with Donepezil and Rivastigmine. MMSE, 6 months after treatment with Donepezil, improved from 20.63 before treatment to 21.83, which is statistically significant (P = 0.04). Also, MMSE, 6 months after treatment with Rivastigmine, improved from 20.03 before treatment to 22.71, which was statistically significant (P = 0.007). About Clock test, there was a significant improvement from 5.74 before treatment to 6.4 after 6 months of treatment with Rivastigmine; while this significant improvement was not seen in patients receiving Donepezil. In two other tests, no significant differences were seen before and after treatment. Also, No significant difference was detected between two groups and so no different effects on these tests between Donepezil and Rivastigmine in 6 months period of treatment.
first_indexed 2024-04-12T20:31:26Z
format Article
id doaj.art-673c79b6cf80469ea123acf74ce23539
institution Directory Open Access Journal
issn 0044-6025
1735-9694
language English
last_indexed 2024-04-12T20:31:26Z
publishDate 2008-04-01
publisher Tehran University of Medical Sciences
record_format Article
series Acta Medica Iranica
spelling doaj.art-673c79b6cf80469ea123acf74ce235392022-12-22T03:17:43ZengTehran University of Medical SciencesActa Medica Iranica0044-60251735-96942008-04-01462EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE R. Abolfazli0 S. Ghazanshahi M. Nazeman1 Alzheimer's disease is the most common degenerative disease of brain. Nowadays, the most common treatment being used to slow down disease progression, include Donepezil , Rivastigmine and Galantamine, which all of them act as inhibitors of acetyl cholinesterase. General purpose of our study was to show effects of treatment with Donepezil and Rivastigmine, as two drugs that commonly used for treatment of AD in Iran and to compare these effects between two drugs. Samples selected from patients who had Alzheimer` disease with DSM IV criteria and were candidate of receiving Donepezil or Rivastigmine, as treatment of AD, for the first time. We used four neuropsychological tests including MMSE, NPI, Clock and Bender to assess patient's cognitive and behavioral changes during treatment with two drugs. Patients divided to two groups (each group 35 cases); Patients with plan of taking Donepezil entered into one of the groups and patients with plan of taking Rivastigmine entered into another. The four tests were completed once before starting treatment and then, 1 month, 3 months and 6 months after treatment with Donepezil and Rivastigmine. MMSE, 6 months after treatment with Donepezil, improved from 20.63 before treatment to 21.83, which is statistically significant (P = 0.04). Also, MMSE, 6 months after treatment with Rivastigmine, improved from 20.03 before treatment to 22.71, which was statistically significant (P = 0.007). About Clock test, there was a significant improvement from 5.74 before treatment to 6.4 after 6 months of treatment with Rivastigmine; while this significant improvement was not seen in patients receiving Donepezil. In two other tests, no significant differences were seen before and after treatment. Also, No significant difference was detected between two groups and so no different effects on these tests between Donepezil and Rivastigmine in 6 months period of treatment.https://acta.tums.ac.ir/index.php/acta/article/view/3451Alzheimer’s diseasedonepezilrivastigmineMMSE (mini mental state examination)NPI (neuro psychiatry inventory)clock drawing test
spellingShingle R. Abolfazli
S. Ghazanshahi M. Nazeman
EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE
Acta Medica Iranica
Alzheimer’s disease
donepezil
rivastigmine
MMSE (mini mental state examination)
NPI (neuro psychiatry inventory)
clock drawing test
title EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE
title_full EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE
title_fullStr EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE
title_full_unstemmed EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE
title_short EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE
title_sort effects of 6 months treatment with donepezil and rivastigmin on results of neuropsychological tests of mmse npi clock and bender in patients with alzheimer s disease
topic Alzheimer’s disease
donepezil
rivastigmine
MMSE (mini mental state examination)
NPI (neuro psychiatry inventory)
clock drawing test
url https://acta.tums.ac.ir/index.php/acta/article/view/3451
work_keys_str_mv AT rabolfazli effectsof6monthstreatmentwithdonepezilandrivastigminonresultsofneuropsychologicaltestsofmmsenpiclockandbenderinpatientswithalzheimersdisease
AT sghazanshahimnazeman effectsof6monthstreatmentwithdonepezilandrivastigminonresultsofneuropsychologicaltestsofmmsenpiclockandbenderinpatientswithalzheimersdisease